Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro).
説明 | Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro). |
ターゲット&IC50 | H+, K+-ATPase:0.29-0.52 μM |
In vitro | Tegoprazan inhibits gastric H+/K+-ATPase in a potassium-competitive and reversible manner and it also inhibits porcine, canine, and human H+/K+-ATPase activity. Tegoprazan (3 μM) inhibits 86% of H+/K+-ATPase activity, whereas the inhibition is decreased to 34% after the dilution of Tegoprazan concentration to 0.15 μM [1]. |
In vivo | Tegoprazan (1.0-3.0 mg/kg, p.o.) reverses the pentagastrin-induced acidified gastric pH to the neutral range. Tegoprazan (1.0 mg/kg, p.o.) effectively and fully inhibits histamine-induced gastric acid secretion in dogs. Tegoprazan (3 mg/kg, p.o.) immediately evokes a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs [1]. |
分子量 | 387.38 |
分子式 | C20H19F2N3O3 |
CAS No. | 942195-55-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (58.08 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tegoprazan 942195-55-3 Membrane transporter/Ion channel ATPase Proton pump pentagastrin Proton Pump acid gastric secretion inhibit Inhibitor inhibitor